The Effects of SSRI Treatment on Neuroblastoma Cell Viability
In the contect of Alzheimer's Disease.
Abstract
Alzheimer’s Disease (AD) claims more lives in the UK than any other condition, 1 in 10, with 55 million individuals affected
worldwide. In AD, the brain’s uptake of important nutrients such as glucose is altered. Selective Serotonin Reuptake Inhibitors (SSRIs) have been shown by recent studies to have potential to slow the advancement of the disease by slowing progression of cognitive dysfunction and restoration of glucose metabolism. Previous studies have utilised the SSRI citalopram to test changes in glucose uptake by cells, assessing its impact as a potential treatment for AD.
References
M. Jones, Dementia is the UK’s Biggest Killer - We Need Political Action to Save Lives, https://www.alzheimersresearchuk.org/news/dementia-is-the-uks-biggest-killer-we-need-political-action-to-save-lives/, (accessed 1 December 2025).
F. Alzenaidi, O. Aldoweesh, S. Alghofaili, A. Fadel, R. Ali Awad Lasloom, D. Alharbi, F. Almalki, A. Ahmad Alkhairi, M. Alharbi, N. Ahmed Alhamdan and A. Y. Azzam, Metabol. Open, 2025, 27, 100389.
R. J. Elsworthy and S. Aldred, Journal of Alzheimer’s Disease, 2019, 69, 651–661.
R. J. Elsworthy, J. A. Crowe, M. C. King, C. Dunleavy, E. Fisher, A. Ludlam, H. R. Parri, E. J. Hill and S. Aldred, Transl. Psychiatry, 2022, 12, 285.
M. Paulzen, S. E. Lammertz, G. Gründer, T. Veselinovic, C. Hiemke and S. C. Tauber, Int. Clin. Psychopharmacol., 2016, 31, 119–126.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Anna Chadwick
This work is licensed under a Creative Commons Attribution 4.0 International License.
